Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism
This study, for people with a condition called hypoparathyroidism, wants to understand how a specific new treatment, Yorvipath, affects their overall well-being. Researchers will be looking closely at how it impacts their quality of life, memory and thinking skills, and even the structure and tiny blood vessels in their brain. They will compare Yorvipath to traditional treatments for hypoparathyroidism to see if there are differences. The main goal is to find out if the new treatment helps improve blood flow in the brain and if this links to better brain health and how people feel. This is a Phase IV study, meaning the treatment is already approved but researchers are learning more about its long-term effects.
At a glance
What is this study about?
You might be interested in this study if you have hypoparathyroidism, a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels. This study is trying to understand more about how different treatments for hypoparathyroidism affect people's lives.
Specifically, researchers are looking at a new treatment called Yorvipath (also known as TransCon PTH) and comparing it to the more traditional calcium and vitamin D treatments, like Alfacalcidol. They want to see if Yorvipath can improve things like your quality of life, how well you think and remember things, and even the health of your brain's structure and tiny blood vessels. Often, people with hypoparathyroidism can experience 'brain fog' or feel generally unwell, and this study aims to see if Yorvipath could help with these symptoms.
The study is in 'Phase IV,' which means Yorvipath is already available for use, but doctors are collecting more information about its long-term effects and how it compares to existing treatments in real-world settings. By taking part, you could help doctors understand more about how to best treat hypoparathyroidism and improve the lives of others with the condition.
Key takeaways
- This study investigates a new hypoparathyroidism treatment, Yorvipath.
- It compares Yorvipath to standard treatments.
- Researchers will look at quality of life, memory, and brain health.
- The study aims to understand blood flow in the brain.
- It's for adults (18+) with chronic hypoparathyroidism.
- Participation helps improve future patient care.
Who may be eligible?
To be eligible for this study, you need to be an adult, 18 years old or older. There is no upper age limit, so people of all adult ages can be considered. Both men and women are welcome to take part in this research.
You must have been diagnosed with chronic hypoparathyroidism, meaning you've had the condition for a while. The study aims to compare how different treatments affect those with this condition.
Beyond these basic requirements, doctors will carefully check your full medical history and current health to make sure the study is safe and right for you. They will explain any other specific criteria you need to meet.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have chronic hypoparathyroidism?
- Are you able to attend regular clinic appointments?
- Are you willing to potentially receive a new study medication?
- Do you understand that both men and women can participate?
What does participation involve?
If you decide to take part, you would be receiving either Yorvipath, given as an injection with a pre-filled pen, or continuing with your current conventional treatment, which might include Alfacalcidol capsules. The study will involve a number of visits to the clinic where doctors will perform various assessments. These assessments will likely include tests to measure your memory and thinking skills (neuropsychological assessment), and scans to look at your brain structure and blood flow. You might also have blood tests and fill out questionnaires about your quality of life.
The total duration of the study would involve regular check-ups and assessments over a period determined by the research team. This helps them track changes and differences between the treatment groups over time. You would receive your study medication (Yorvipath or ongoing conventional therapy) throughout your participation.
Potential risks and benefits
Locations (1)
- —UnverifiedDenmark
Common questions
What is hypoparathyroidism?
It's a rare condition where your body doesn't produce enough parathyroid hormone, which helps control calcium levels in your blood.
What is Yorvipath?
It's a newer medication designed to replace the missing parathyroid hormone in people with hypoparathyroidism.
Will I know if I'm getting the new treatment?
The study aims to compare treatments, so you would be assigned to either Yorvipath or your usual treatment. The research team will explain how this works when you discuss joining.
What does quality of life mean in this study?
It refers to how your health and treatment affect your daily life, your well-being, and how you feel generally.
How long will the study last?
The research team will be able to give you a clear timeline of how long you'd be involved during your initial discussions.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.